Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF)
Our findings demonstrate that targeting titin stiffness with Rbm20-ASOs can serve as an alternative or adjunctive therapeutic strategy for HFpEF to restore cardiac function and prevent further organ damage. The approach may offer benefits even in the presence of phenotypic heterogeneity and unresolved systemic comorbidities.
Authors
- Michael Gotthardt (ORCID: https://orcid.org/0000-0003-1788-3172)
- Mei Methawasin (ORCID: https://orcid.org/0000-0002-2509-1936)
- Gerrie P. Farman (ORCID: https://orcid.org/0000-0001-8095-8179)
- Henk L. M. Granzier (ORCID: https://orcid.org/0000-0002-9516-407X)
- Wei Guo (ORCID: https://orcid.org/0000-0002-9158-8107)
- John E. Smith (ORCID: https://orcid.org/0000-0002-0888-1274)
- Zaynab Hourani
- Stefan Meinke (ORCID: https://orcid.org/0000-0001-5083-3383)
- Michaël Radkë (ORCID: https://orcid.org/0000-0003-0112-9917)
Institutions
- University of Wisconsin–Madison (US)
- University of Arizona (US)
- Max Delbrück Center (DE)
- German Centre for Cardiovascular Research (DE)
- University of Missouri (US)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Cardiovascular Research
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1093/cvr/cvaf171
- Primary Topic
- RNA Research and Splicing
- Type
- article
- Field-Weighted Citation Impact
- 0.00